智通财经APP讯，君实生物(01877)公布，公司主席兼执行董事熊俊先生计划增持公司股份，拟自2025年4月12日起12个月内通过上海证券交易所交易系统与香港联合交易所有限公司允许的方式(包括但不限于集中竞价和大宗交易)增持A股股份及H股股份，合计增持金额不低于人民币 1亿元，其中A股增持金额不低于人民币5000万元。
于增持计划前，熊先生及其一致行动人士于合共约1.84亿股股份中拥有权益，占本公告日期公司已发行股本总额约18.67%。
据熊俊先生告知，彼对公司未来发展充满信心并认可公司长期投资价值，在遵守适用法律法规的情况下，熊俊先生将根据公司股票价格波动情况及资本市场整体趋势择机增持A股股份及H股股份。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.